Overview
Intra-articular and peri-articular glucocorticoid (GC) injections are common in sports medicine. However, from 1st January 2022, all injectable GC routes (including intra-articular administration (IA)) will be prohibited in-competition by World Anti-Doping Agency (WADA). Due to these rules, an IA GC treatment out-of-competition could result in an adverse analytical finding (AAF) in-competition if the washout period is not clearly defined. The aim of this study is to determine the urinary excretion profile of triamcinolone acetonide following IA to help in the definition of the washout periods.
Eligibility
Inclusion Criteria:
- Sports practice at least 4h / week
- No comorbidities against indicating intra-articular knee injection
- Subject with a knee disease requiring intra-articular injection of GCs
Exclusion Criteria:
- Subject with glucocorticoid (GC) allergy or GC medical contraindication
- Pregnant women or women of childbearing potential without effective contraception
- Washout period of all injectable routes and systemic use of GCs less than 3 months